The System

RAPID-B® is a high performance, integrated microbiology/infectious disease diagnostic system. The system uses hardware, software and wetware that are specifically designed for optimal performance.

Sample Analysis

The RAPID-B approach uniquely enables the analysis of samples containing a complex matrix as well as substantial quantities of ‘background microflora’. The RAPID-B process begins by simply adding proprietary, high specificity reagents to the sample.

Easy-to-use System

The sample is automatically drawn into the system. A special nozzle within the system causes all particles within the system, including bacterial microflora, to line up in single file.

Laser and Sensors

The instrument laser and sensors are all indexed to common location via a rigid, stable chassis, eliminating the need for frequent recalibration.

Multi-dimensional Analysis

Each particle is hit by a laser (shown in blue) and the resulting signal analyzed in multiple dimensions including multiple fluorescent and light scatter dimensions

Phenotype Properties and Reagents

Signal is analyzed in multiple dimensions including those associated with phenotype properties of the bacteria (size, shape, refractive index etc) along with response to immunological reagents and DNA intercalating dyes.

'Real-time' Processing

‘Real time’ processing provides results while the sample is being run. Simple pass/fail results are presented along with the total number of live, viable target bacteria in the sample and other specific sample ID information.

Easy-to-use User Interface

Built on top of the analytical complexity is a very simple user interface that tells the technician whether or not each sample passes or fails the criteria established by the lab manager.

High Sensitivity Reagents

Primary targeting is accomplished with custom, optimized immuno-based reagents that are designed to broadly target the cell surface of target bacteria without cross-reactivity to similar non-target bacteria. The immuno portion of reagents are conjugated to a laser excitable fluorophore excited by the laser. A DNA intercalating dye works in conjunction with primary targeting reagents to indicate only live viable cells. Buffers, conditioners and other additives allow use within a complex matrix and without the need for isolation or elaborate sample preparation requirements.

High Selectivity Electronic Filtering

Each particle within the sample is analyzed in a multitude of dimensions including size, shape, aspect ratio, immuno-reagent fluorescent response and viability stain fluorescent response. This simultaneous, multi-dimensional analysis enables comprehensive assessment of each particle and identification of a single target bacterium within the sample. Further, the RAPID-B multi-dimensional electronic analysis filters noise without impacting bacteria signal. This allows analysis even in the presence of substantial amounts of background matrix. This results in faster analysis, less sample preparation while yielding quantitative identification of live viable pathogen within the sample.

RAPID-B Methodology

a unique approach that interrogates each individual cell across multiple parameters simultaneously and in real time

This approach delivers that fastest time for Sample to Result. The RAPID-B enrichment time for single cell sensitivity is required to ensure that there is a cell of interest within the sampling volume

Competitive Methodologies

Competitive systems much first ensure that the sample matrix is separated from the organism or organisms of interest. Then due to their lower sensitivity, these other approaches require significantly more cells for detection. The end result is a significantly longer for Sample to Result, time that is measured in days.

News Feed

Vivione Biosciences Inc. Receives AOAC Certification, Positions Brand for Fast Growth in Food Industry

Vivione Signs Strategic Alliance Agreement with IEH and Launches New Oil and Gas Product Offerings

Vivione Biosciences Inc. announces agreement with Litmus, LLC for Molecular Design Rights

Vivione Biosciences Inc. Enters Agreement with World’s Largest Public Relations Firm, Edelman

Vivione Biosciences Inc. receives coveted Letter of No Objection (LNO) designation from US Department

Vivione Biosciences signs agreement with CMS Technology

Vivione Biosciences Inc. chief executive officer interviewed by CEOCFO Magazine

Vivione Biosciences announces closing of the private placement offering with the arkansas venture capital

Vivione Biosciences Inc. forms strategic alliance with AriBio, Inc.

FDA and Vivione Enter into a New Three-Year Cooperative Research and Development Agreement

Vivione Biosciences set for food safety breakthrough

Vivione Biosciences In Position for a Big Year

Vivione Biosciences Inc. is pleased to announce a new development relationship

Vivione Biosciences Inc. signs collaboration with University of Arkansas Department

PACEpartners Inc. Announces Name Change to Vivione Biosciences Inc.

PACEpartners Inc. Retains Investor Relations Firm and Settles Debt

PACEpartners Inc. Completes Qualifying Transaction and Resumes Trading

PACEpartners Inc. Announces Closing of its Qualifying Transaction

Number of U.S. Foodborne Illness Cases Stalled: CDC

E. Coli Fears Prompt Massive Frozen Food Recall